chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Haemoglobin, Hypokalaemia, Influenza virus test negative, Limb injury, Metabolic function test abnormal
Clinical narrative: Patient is a 83 y.o. male with history of HFpEF, atrial fibrillation, CKD, COPD, BPH, depression presented with COVID.   Patient reports he began feeling poorly about 3 days ago with generalized fatigue, poor appetite, fever, and SOB.  Patient reports having his COVID vaccines.   In the ED vitals are as follows, temperature 98.6, blood pressure 108/59, heart rate 101, RR 22, and oxygen saturation of 93% on 4L. Labs results were significant for K 3.1, BUN 28, creatinine 1.31, H/H 7.2/22.5, platelet 116, and glucose 107. The rest of the CBC and CMP were within normal limits. Troponin 127-114. Flu swab negative. Chest x-ray showed no significant change in right greater than left pleural effusions with adjacent a  with adjacent atelectasis. Patient was given cefepime, furosemide, duoneb, NSS, and 1 unit PRBC. Patient admitted for observation.    Clinical Summary 1. E faecalis bacteremia. Biventricular pacemaker in place. Bioprosthetic mitral valve in place. Endocarditis. TV vegetation: Blood cultures 2 out of 2 7/26 returned positive for e faecalis sensitive to ampicillin. 7/27 Echo showed EF 55%, mild AS, bioprosthetic mitral valve leaflets are not well visualized, small tricuspid valve vegetation visualized. S/p 2 days of maxipime 2g, 3 days of zosyn. Ampicillin 2g q4h started 7/29; continue. Repeat blood culture 7/30 still positive despite 5 days of abx. ID consulted who recommends transfer as concern for device infection and needs TEE. IV ceftriaxone 2g q12h started 7/31 for endocarditis per ID recs. Repeat BC 8/1 NGTD. Transfer requested and accepted 7/31; patient was transferred to Hospital on 8/3 2. UTI: Urine culture positive 7/26 E faecalis sensitive to ampicillin. Repeat urine culture 7/31 negative 3. COVID. COPD exacerbation: CT pulmonary arteries 7/26 no PE, small left and moderate right sided pleural effusion with adjacent atelectasis. dexamethasone 6mg started 7/25. s/p 5 days of IV remdesivir (completed on 7/30). Seen by pulmonology. MRSA positive 7/27 4. Anemia: On admit H/H 7.2/22.5. s/p 1 unit PRBC transfused 7/26. Last H/H of 9.2/29.6 on 8/2. 5. HFpEF: Echo 10/24 showed EF 65%, abnormal septal motion, mild AS, thickened bioprosthetic mitral valve leaflets. 7/26 BNP 27594. continue home bumetanide 1mg BID. strict I/O 6. Hypokalemia - resolved: K 3.1 on admit; today K 3.9. Continue to monitor and replete as needed 7. Left ankle wound: Chronic. Established with wound care/hospital outpatient. Wound care consulted; seen 7/28/2023 8. Atrial fibrillation: Continue home metoprolol 15mg BID and rivaroxaban 15mg daily 9. BPH: Continue home finasteride 5mg daily and tamsulosin 0.4mg daily 10. Depression: Continue home excitalopram 5mg daily 11. Thrombocytopenia, POA: Mild. Continue to monitor
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Mitral valve thickening, Platelet count decreased, Pleural effusion, Pyrexia, Red blood cell transfusion
Clinical narrative: Patient is a 83 y.o. male with history of HFpEF, atrial fibrillation, CKD, COPD, BPH, depression presented with COVID.   Patient reports he began feeling poorly about 3 days ago with generalized fatigue, poor appetite, fever, and SOB.  Patient reports having his COVID vaccines.   In the ED vitals are as follows, temperature 98.6, blood pressure 108/59, heart rate 101, RR 22, and oxygen saturation of 93% on 4L. Labs results were significant for K 3.1, BUN 28, creatinine 1.31, H/H 7.2/22.5, platelet 116, and glucose 107. The rest of the CBC and CMP were within normal limits. Troponin 127-114. Flu swab negative. Chest x-ray showed no significant change in right greater than left pleural effusions with adjacent a  with adjacent atelectasis. Patient was given cefepime, furosemide, duoneb, NSS, and 1 unit PRBC. Patient admitted for observation.    Clinical Summary 1. E faecalis bacteremia. Biventricular pacemaker in place. Bioprosthetic mitral valve in place. Endocarditis. TV vegetation: Blood cultures 2 out of 2 7/26 returned positive for e faecalis sensitive to ampicillin. 7/27 Echo showed EF 55%, mild AS, bioprosthetic mitral valve leaflets are not well visualized, small tricuspid valve vegetation visualized. S/p 2 days of maxipime 2g, 3 days of zosyn. Ampicillin 2g q4h started 7/29; continue. Repeat blood culture 7/30 still positive despite 5 days of abx. ID consulted who recommends transfer as concern for device infection and needs TEE. IV ceftriaxone 2g q12h started 7/31 for endocarditis per ID recs. Repeat BC 8/1 NGTD. Transfer requested and accepted 7/31; patient was transferred to Hospital on 8/3 2. UTI: Urine culture positive 7/26 E faecalis sensitive to ampicillin. Repeat urine culture 7/31 negative 3. COVID. COPD exacerbation: CT pulmonary arteries 7/26 no PE, small left and moderate right sided pleural effusion with adjacent atelectasis. dexamethasone 6mg started 7/25. s/p 5 days of IV remdesivir (completed on 7/30). Seen by pulmonology. MRSA positive 7/27 4. Anemia: On admit H/H 7.2/22.5. s/p 1 unit PRBC transfused 7/26. Last H/H of 9.2/29.6 on 8/2. 5. HFpEF: Echo 10/24 showed EF 65%, abnormal septal motion, mild AS, thickened bioprosthetic mitral valve leaflets. 7/26 BNP 27594. continue home bumetanide 1mg BID. strict I/O 6. Hypokalemia - resolved: K 3.1 on admit; today K 3.9. Continue to monitor and replete as needed 7. Left ankle wound: Chronic. Established with wound care/hospital outpatient. Wound care consulted; seen 7/28/2023 8. Atrial fibrillation: Continue home metoprolol 15mg BID and rivaroxaban 15mg daily 9. BPH: Continue home finasteride 5mg daily and tamsulosin 0.4mg daily 10. Depression: Continue home excitalopram 5mg daily 11. Thrombocytopenia, POA: Mild. Continue to monitor
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Staphylococcus test positive, Thrombocytopenia, Tricuspid valve disease, Troponin, Urinary tract infection
Clinical narrative: Patient is a 83 y.o. male with history of HFpEF, atrial fibrillation, CKD, COPD, BPH, depression presented with COVID.   Patient reports he began feeling poorly about 3 days ago with generalized fatigue, poor appetite, fever, and SOB.  Patient reports having his COVID vaccines.   In the ED vitals are as follows, temperature 98.6, blood pressure 108/59, heart rate 101, RR 22, and oxygen saturation of 93% on 4L. Labs results were significant for K 3.1, BUN 28, creatinine 1.31, H/H 7.2/22.5, platelet 116, and glucose 107. The rest of the CBC and CMP were within normal limits. Troponin 127-114. Flu swab negative. Chest x-ray showed no significant change in right greater than left pleural effusions with adjacent a  with adjacent atelectasis. Patient was given cefepime, furosemide, duoneb, NSS, and 1 unit PRBC. Patient admitted for observation.    Clinical Summary 1. E faecalis bacteremia. Biventricular pacemaker in place. Bioprosthetic mitral valve in place. Endocarditis. TV vegetation: Blood cultures 2 out of 2 7/26 returned positive for e faecalis sensitive to ampicillin. 7/27 Echo showed EF 55%, mild AS, bioprosthetic mitral valve leaflets are not well visualized, small tricuspid valve vegetation visualized. S/p 2 days of maxipime 2g, 3 days of zosyn. Ampicillin 2g q4h started 7/29; continue. Repeat blood culture 7/30 still positive despite 5 days of abx. ID consulted who recommends transfer as concern for device infection and needs TEE. IV ceftriaxone 2g q12h started 7/31 for endocarditis per ID recs. Repeat BC 8/1 NGTD. Transfer requested and accepted 7/31; patient was transferred to Hospital on 8/3 2. UTI: Urine culture positive 7/26 E faecalis sensitive to ampicillin. Repeat urine culture 7/31 negative 3. COVID. COPD exacerbation: CT pulmonary arteries 7/26 no PE, small left and moderate right sided pleural effusion with adjacent atelectasis. dexamethasone 6mg started 7/25. s/p 5 days of IV remdesivir (completed on 7/30). Seen by pulmonology. MRSA positive 7/27 4. Anemia: On admit H/H 7.2/22.5. s/p 1 unit PRBC transfused 7/26. Last H/H of 9.2/29.6 on 8/2. 5. HFpEF: Echo 10/24 showed EF 65%, abnormal septal motion, mild AS, thickened bioprosthetic mitral valve leaflets. 7/26 BNP 27594. continue home bumetanide 1mg BID. strict I/O 6. Hypokalemia - resolved: K 3.1 on admit; today K 3.9. Continue to monitor and replete as needed 7. Left ankle wound: Chronic. Established with wound care/hospital outpatient. Wound care consulted; seen 7/28/2023 8. Atrial fibrillation: Continue home metoprolol 15mg BID and rivaroxaban 15mg daily 9. BPH: Continue home finasteride 5mg daily and tamsulosin 0.4mg daily 10. Depression: Continue home excitalopram 5mg daily 11. Thrombocytopenia, POA: Mild. Continue to monitor
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Ventricular dyskinesia
Clinical narrative: Patient is a 83 y.o. male with history of HFpEF, atrial fibrillation, CKD, COPD, BPH, depression presented with COVID.   Patient reports he began feeling poorly about 3 days ago with generalized fatigue, poor appetite, fever, and SOB.  Patient reports having his COVID vaccines.   In the ED vitals are as follows, temperature 98.6, blood pressure 108/59, heart rate 101, RR 22, and oxygen saturation of 93% on 4L. Labs results were significant for K 3.1, BUN 28, creatinine 1.31, H/H 7.2/22.5, platelet 116, and glucose 107. The rest of the CBC and CMP were within normal limits. Troponin 127-114. Flu swab negative. Chest x-ray showed no significant change in right greater than left pleural effusions with adjacent a  with adjacent atelectasis. Patient was given cefepime, furosemide, duoneb, NSS, and 1 unit PRBC. Patient admitted for observation.    Clinical Summary 1. E faecalis bacteremia. Biventricular pacemaker in place. Bioprosthetic mitral valve in place. Endocarditis. TV vegetation: Blood cultures 2 out of 2 7/26 returned positive for e faecalis sensitive to ampicillin. 7/27 Echo showed EF 55%, mild AS, bioprosthetic mitral valve leaflets are not well visualized, small tricuspid valve vegetation visualized. S/p 2 days of maxipime 2g, 3 days of zosyn. Ampicillin 2g q4h started 7/29; continue. Repeat blood culture 7/30 still positive despite 5 days of abx. ID consulted who recommends transfer as concern for device infection and needs TEE. IV ceftriaxone 2g q12h started 7/31 for endocarditis per ID recs. Repeat BC 8/1 NGTD. Transfer requested and accepted 7/31; patient was transferred to Hospital on 8/3 2. UTI: Urine culture positive 7/26 E faecalis sensitive to ampicillin. Repeat urine culture 7/31 negative 3. COVID. COPD exacerbation: CT pulmonary arteries 7/26 no PE, small left and moderate right sided pleural effusion with adjacent atelectasis. dexamethasone 6mg started 7/25. s/p 5 days of IV remdesivir (completed on 7/30). Seen by pulmonology. MRSA positive 7/27 4. Anemia: On admit H/H 7.2/22.5. s/p 1 unit PRBC transfused 7/26. Last H/H of 9.2/29.6 on 8/2. 5. HFpEF: Echo 10/24 showed EF 65%, abnormal septal motion, mild AS, thickened bioprosthetic mitral valve leaflets. 7/26 BNP 27594. continue home bumetanide 1mg BID. strict I/O 6. Hypokalemia - resolved: K 3.1 on admit; today K 3.9. Continue to monitor and replete as needed 7. Left ankle wound: Chronic. Established with wound care/hospital outpatient. Wound care consulted; seen 7/28/2023 8. Atrial fibrillation: Continue home metoprolol 15mg BID and rivaroxaban 15mg daily 9. BPH: Continue home finasteride 5mg daily and tamsulosin 0.4mg daily 10. Depression: Continue home excitalopram 5mg daily 11. Thrombocytopenia, POA: Mild. Continue to monitor
Age: 73.0
Sex: F
Vaccine: RSV
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: patient reports a bump on arm where injection was given. redness around the area, some pain and warmth on injection site.
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, Angiogram pulmonary normal, Asthenia, COVID-19, Cardiomyopathy
Clinical narrative: Covid-19 Infection Acute Hypoxemic Respiratory Failure, resolved -Symptom onset 7/29, presented 7/31 shortness of breath, cough, weakness -Covid-19 (+) 7/31 on presentation; vaccinated with Pfizer, last booster 1/2022 -CXR, CTPA without infiltrate/PE -S/p steroid therapy x2days, remdesivir x3days; given continued clinical improvement and respiratory stability further therapy deferred on discharge   Nonischemic Cardiomyopathy History of AICD Progressive Multiple Sclerosis Hypothyroidism GERD
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Chest X-ray normal, Cough, Dyspnoea, Malaise, SARS-CoV-2 test positive
Clinical narrative: Covid-19 Infection Acute Hypoxemic Respiratory Failure, resolved -Symptom onset 7/29, presented 7/31 shortness of breath, cough, weakness -Covid-19 (+) 7/31 on presentation; vaccinated with Pfizer, last booster 1/2022 -CXR, CTPA without infiltrate/PE -S/p steroid therapy x2days, remdesivir x3days; given continued clinical improvement and respiratory stability further therapy deferred on discharge   Nonischemic Cardiomyopathy History of AICD Progressive Multiple Sclerosis Hypothyroidism GERD
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Blood glucose normal, Blood iron, COVID-19
Clinical narrative: Patient is a 45 y.o. female patient of System, Provider Not In with history of iron deficiency anemia, possible COPD presented to Hospital with Acute hypoxemic respiratory failure requiring BIPAP and found to be COVID 19 Positive. Transitioned to 2L NC and finally to RA. She was admitted for further eval and treatment.      Acute hypoxemic respiratory failure Sepsis due to COVID Acute COVID pneumonia Presents via EMS with shortness of breath x1 week. Initially required bipap, transitioned to 2L NC after DuoNeb treatment. On admission, tachycardic and tachypnic. Febrile at 100.7 COVID+, no leukocytosis -CTPA: bilateral small ground glass infiltrates -Started Remdesivir and dexamethasone and duonebs -Pt is off O2, stable for discharge -Discharge on prednisone and antitussives     Chronic iron deficiency anemia Hgb 11.4 on admission, Fe 11, Fe Sat 3, ferritin 30 Start oral Fe   Hyperglycemia BG on admission 189, A1c 5.7 Most likely will increase due to corticosteroids   Obesity BMI 37.76 -Encourage dietary and lifestyle modifications Recheck A1c in 3 mn
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Condition aggravated, Dyspnoea, Glycosylated haemoglobin normal, Haemoglobin
Clinical narrative: Patient is a 45 y.o. female patient of System, Provider Not In with history of iron deficiency anemia, possible COPD presented to Hospital with Acute hypoxemic respiratory failure requiring BIPAP and found to be COVID 19 Positive. Transitioned to 2L NC and finally to RA. She was admitted for further eval and treatment.      Acute hypoxemic respiratory failure Sepsis due to COVID Acute COVID pneumonia Presents via EMS with shortness of breath x1 week. Initially required bipap, transitioned to 2L NC after DuoNeb treatment. On admission, tachycardic and tachypnic. Febrile at 100.7 COVID+, no leukocytosis -CTPA: bilateral small ground glass infiltrates -Started Remdesivir and dexamethasone and duonebs -Pt is off O2, stable for discharge -Discharge on prednisone and antitussives     Chronic iron deficiency anemia Hgb 11.4 on admission, Fe 11, Fe Sat 3, ferritin 30 Start oral Fe   Hyperglycemia BG on admission 189, A1c 5.7 Most likely will increase due to corticosteroids   Obesity BMI 37.76 -Encourage dietary and lifestyle modifications Recheck A1c in 3 mn
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperglycaemia, Iron deficiency anaemia, Lung opacity, Obesity, Positive airway pressure therapy
Clinical narrative: Patient is a 45 y.o. female patient of System, Provider Not In with history of iron deficiency anemia, possible COPD presented to Hospital with Acute hypoxemic respiratory failure requiring BIPAP and found to be COVID 19 Positive. Transitioned to 2L NC and finally to RA. She was admitted for further eval and treatment.      Acute hypoxemic respiratory failure Sepsis due to COVID Acute COVID pneumonia Presents via EMS with shortness of breath x1 week. Initially required bipap, transitioned to 2L NC after DuoNeb treatment. On admission, tachycardic and tachypnic. Febrile at 100.7 COVID+, no leukocytosis -CTPA: bilateral small ground glass infiltrates -Started Remdesivir and dexamethasone and duonebs -Pt is off O2, stable for discharge -Discharge on prednisone and antitussives     Chronic iron deficiency anemia Hgb 11.4 on admission, Fe 11, Fe Sat 3, ferritin 30 Start oral Fe   Hyperglycemia BG on admission 189, A1c 5.7 Most likely will increase due to corticosteroids   Obesity BMI 37.76 -Encourage dietary and lifestyle modifications Recheck A1c in 3 mn
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test positive, Sepsis, Serum ferritin normal, Tachycardia
Clinical narrative: Patient is a 45 y.o. female patient of System, Provider Not In with history of iron deficiency anemia, possible COPD presented to Hospital with Acute hypoxemic respiratory failure requiring BIPAP and found to be COVID 19 Positive. Transitioned to 2L NC and finally to RA. She was admitted for further eval and treatment.      Acute hypoxemic respiratory failure Sepsis due to COVID Acute COVID pneumonia Presents via EMS with shortness of breath x1 week. Initially required bipap, transitioned to 2L NC after DuoNeb treatment. On admission, tachycardic and tachypnic. Febrile at 100.7 COVID+, no leukocytosis -CTPA: bilateral small ground glass infiltrates -Started Remdesivir and dexamethasone and duonebs -Pt is off O2, stable for discharge -Discharge on prednisone and antitussives     Chronic iron deficiency anemia Hgb 11.4 on admission, Fe 11, Fe Sat 3, ferritin 30 Start oral Fe   Hyperglycemia BG on admission 189, A1c 5.7 Most likely will increase due to corticosteroids   Obesity BMI 37.76 -Encourage dietary and lifestyle modifications Recheck A1c in 3 mn
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Tachypnoea, Transferrin saturation
Clinical narrative: Patient is a 45 y.o. female patient of System, Provider Not In with history of iron deficiency anemia, possible COPD presented to Hospital with Acute hypoxemic respiratory failure requiring BIPAP and found to be COVID 19 Positive. Transitioned to 2L NC and finally to RA. She was admitted for further eval and treatment.      Acute hypoxemic respiratory failure Sepsis due to COVID Acute COVID pneumonia Presents via EMS with shortness of breath x1 week. Initially required bipap, transitioned to 2L NC after DuoNeb treatment. On admission, tachycardic and tachypnic. Febrile at 100.7 COVID+, no leukocytosis -CTPA: bilateral small ground glass infiltrates -Started Remdesivir and dexamethasone and duonebs -Pt is off O2, stable for discharge -Discharge on prednisone and antitussives     Chronic iron deficiency anemia Hgb 11.4 on admission, Fe 11, Fe Sat 3, ferritin 30 Start oral Fe   Hyperglycemia BG on admission 189, A1c 5.7 Most likely will increase due to corticosteroids   Obesity BMI 37.76 -Encourage dietary and lifestyle modifications Recheck A1c in 3 mn
Age: 54.0
Sex: F
Vaccine: VARZOS
Symptoms: Dizziness, Hypotension
Clinical narrative: Patient reported felling faint, light headed about 10 minutes after receiving the vaccine. We gave patient water and she said she felt much better after that. We tried to check her blood pressure couple time, but the monitor gave us an error.  Her blood pressure was taken by the Medic Team and it was low, like 80/60. They let her lie down for few minutes and rechecked twice and the last reading was back to almost normal like 112/xx (don't remember). Patient was taken care by the Medic Team from there.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood test, Eye pruritus, Paraesthesia, Pruritus
Clinical narrative: Ever since I had the vaccine. I have grass and other things coming out of my skin. All I do is itch morning to night. Very itchy, it comes in my eyes, out my feet everywhere. My son and husband had it too.
Age: 32.0
Sex: F
Vaccine: FLU4
Symptoms: Dizziness
Clinical narrative: Patient called the pharmacy about 45 minutes after vaccination and reported that they were experiencing dizziness. They were advised to rest under the supervision of the people who they were with at the time and to seek medical help if the symptoms worsened. When I followed up a couple hours later they reported they had ended up going to the ER via ambulance. When asked about treatment they said the ER was taking forever and they ended up walking out because they started to feel much better.
Age: 68.0
Sex: U
Vaccine: FLU4
Symptoms: Chills, Fatigue, Headache, Mobility decreased, Pyrexia
Clinical narrative: Couldn't move the next day. experienced a fever/chills, headache and was so tired. She felt better today but, wanted the AE reported
Age: 16.0
Sex: F
Vaccine: COVID19, FLU3, UNK
Symptoms: Seizure
Clinical narrative: Seizure - less than 1 minute  recovered in office sent to hospital
Sex: U
Vaccine: PNC15
Symptoms: Syringe issue
Clinical narrative: 2 syringe breaks of VAXNEUVANCE following administration that was reported in a PQC case on 08/02/2023; 2 syringe breaks of VAXNEUVANCE following administration that was reported in a PQC case on 08/02/2023; No other AE; This spontaneous report was received from a physician assistant and refers to unknown patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported.  On an unknown date, patients were vaccinated with pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) injection, unk, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided). It was reported that 2 syringe breaks of pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) following administration (poor quality device used, syringe issue). The reporter confirmed there were no injuries and no symptoms reported (no adverse event).  This is a non-valid report due to lack of patients' identifiers.
Sex: F
Vaccine: HPV9
Symptoms: Injection site pain
Clinical narrative: Caller stated a pharmacy technician mentioned to her that when both the pharmacy technician and the pharmacy technician's daughter received the GARDASIL9 vaccine, they both experienced injection site pain; This spontaneous report was received from a pharmacist technician and refers to herself, a female patient of unknown age. Information regarding the patient's medical history, concurrent conditions, concomitant therapies and historical drugs, was not provided.  On an unknown date, the patient started therapy with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered for prophylaxis (strength, dosage regimen, lot #, expiry date, and route of administration were not provided).  On an unknown date, the reporter stated that both the pharmacy technician and the pharmacy technician's daughter (reported in MARRS# 2309USA002865), experienced injection site pain (vaccination site pain.)  The causal relationship between vaccination site pain and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was not reported.; Sender's Comments:  US-009507513-2309USA002865:
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: no adverse event; Inbound call from a medical assistant with a physician on the back line reporting AE for VARIVAX.  TE case filed under 02458467. AE details were provided by medical assistant. No symptoms reported. No additional AE/PQC.  ?    Names of vaccines invo; This spontaneous report was received from a medical assistant with a physician and refers to an unknown age and gender patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 26-JUL-2023, the patient received the second dose of varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection which was improperly stored for 1 hour 30 minutes 0 seconds in temperature of - 12.48 degrees Celsius (C), no previous temperature excursion (Improper storage of product in use), (lot #x006983, has been verified to be a valid lot number, expiration date was reported as 07-MAR-2025), administered subcutaneously for prophylaxis (strength was not provided). No symptoms reported. No additional adverse event (AE)/PQC.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2308USA009014:
Sex: F
Vaccine: HPV9
Symptoms: Injection site pain
Clinical narrative: Caller stated a pharmacy technician mentioned to her that when both the pharmacy technician and the pharmacy technician's daughter received the GARDASIL9 vaccine, they both experienced injection site pain; This spontaneous report was received from a pharmacist technician and refers to her daughter, a female patient of unknown age.  On an unknown date, the patient started therapy with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered for prophylaxis (strength, dosage regimen, lot #, expiry date, and route of administration were not provided).  On an unknown date, the reporter stated that both the pharmacy technician (reported in MARRS# 2308USA005260) and the pharmacy technician's daughter, experienced injection site pain (vaccination site pain.)  The causal relationship between vaccination site pain and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was not reported.; Sender's Comments:  US-009507513-2308USA005260:
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Myocarditis
Clinical narrative: contracted the Delta virus; contracted myocarditis/the myocarditis got really bad; This spontaneous case was reported by a patient and describes the occurrence of MYOCARDITIS (contracted myocarditis/the myocarditis got really bad) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 015M20A and 010M20A) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Patient did not report any medical history or condition.    On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced MYOCARDITIS (contracted myocarditis/the myocarditis got really bad) (seriousness criterion medically significant). In July 2021, the patient experienced COVID-19 (contracted the Delta virus). At the time of the report, MYOCARDITIS (contracted myocarditis/the myocarditis got really bad) had resolved and COVID-19 (contracted the Delta virus) outcome was unknown.            Concomitant medication not reported.   She received the second dose in Mar 2021. Immediately after she contracted myocarditis, which she reported to her doctor. At the end of Jul 2021, she contracted the Delta virus, and the myocarditis got really bad. She mentioned during that time she was moving, and she was able to make the move.  Treatment medication not reported. Company comment- This is a spontaneous case concerning a 71-year-old female patient with no medical history reported who experienced the expected and serious (medically significant) event myocarditis immediately after a dose of mRNA-1273 vaccine, given as a second dose of COVID vaccine schedule, was administered. It was reported that immediately after she received the vaccine, she contracted myocarditis. Four months after, she contracted the Delta virus, and the myocarditis got really bad. She mentioned that during that time she was moving, and she was able to make the move. Patient now feels good, and her health is better. No further details were provided for medical review.  The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.
Age: 85.0
Sex: M
Vaccine: PNC20
Symptoms: Cellulitis, Erythema, Swelling
Clinical narrative: possible cellulitis; redness; swelling; This is a spontaneous report received from contactable reporter(s) (Nurse).  An 85-year-old male patient received pneumococcal 20-val conj vac (dipht CRM197 protein) (PREVNAR 20), on 21Aug2023 as dose 1, single (Lot number: GT0538) at the age of 85 years, in right deltoid for immunisation. The patient's relevant medical history included: "DM" (unspecified if ongoing); "HTN" (unspecified if ongoing); "BPH" (unspecified if ongoing); "CVA" (unspecified if ongoing); "Hyperlipidemia" (unspecified if ongoing). Patient had no known drug allergy. The patient's concomitant medications were not reported. The following information was reported: CELLULITIS (intervention required, medically significant) with onset 26Aug2023, outcome "recovering", described as "possible cellulitis"; ERYTHEMA (intervention required) with onset 26Aug2023, outcome "recovering", described as "redness"; SWELLING (intervention required) with onset 26Aug2023, outcome "recovering". Therapeutic measures were taken as a result of cellulitis, erythema, swelling included Antibiotics. Additional information: The vaccine was administered in Doctor's office/urgent care. Patient did not receive any other vaccines on the same date. The report was reported as non-serious by reporter.  Causality for "possible cellulitis", "redness" and "swelling" was determined associated to device constituent of pneumococcal 20-val conj vac (dipht crm197 protein) (malfunction).  The information on the batch/lot number for pneumococcal 20-val conj vac (dipht crm197 protein)  has been requested and will be submitted if and when received.; Sender's Comments: A possibly contributory role of administration with PREVNAR 20 in triggering the onset of possible cellulitis with erythema, swelling might not be fully excluded, considering the temporal relationship.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate
Age: 1.17
Sex: F
Vaccine: HIBV
Symptoms: Expired product administered, Product preparation error
Clinical narrative: ACTHIB was reconstituted with an incorrect diluent (with no reported adverse event); product had expired on 13AUG2023 (with no reported adverse event); Initial information received on 05-Sep-2023 regarding an unsolicited valid non-serious case received from a other health professional (nurse).  This case involves a 14-month-old female patient for whom administered expired HIB (PRP/T) vaccine [ACT-HIB] which was reconstituted with an incorrect diluent with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Diphtheria Vaccine Toxoid, Pertussis Vaccine Acellular, Tetanus Vaccine Toxoid (DTAP) and Varicella Zoster Vaccine (Varicella Vaccine) for Prophylactic vaccination.  On 05-Sep-2023, the patient received an expired dose of 0.5 ml 1x (frequency: once) suspect HIB (PRP/T) vaccine Powder and solvent for solution for injection of standard strength (lot: UJ803AA, Expiry date: 13-Aug-2023) via intramuscular route in the left thigh for Immunization which was reconstituted with an incorrect diluent with no reported adverse event (expired product administered)  (product preparation error) (latency: same day).  Action taken: not applicable.  At time of reporting, the outcome was Unknown for both the events.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 53.0
Sex: F
Vaccine: DTAP
Symptoms: Dizziness, Ear discomfort, Glossodynia, Nausea, Palpitations
Clinical narrative: Given vaccines at 10:30 a.m By 1:15 p.m extreme dizziness (room felt like it was spinning), extreme nausea, felt like fainting, ears felt like everything was far away, could feel heart pounding, next day tongue slightly swollen and sore.  Vertigo lasting more than 5 days.
Age: 53.0
Sex: F
Vaccine: DTAP
Symptoms: Swollen tongue, Vertigo
Clinical narrative: Given vaccines at 10:30 a.m By 1:15 p.m extreme dizziness (room felt like it was spinning), extreme nausea, felt like fainting, ears felt like everything was far away, could feel heart pounding, next day tongue slightly swollen and sore.  Vertigo lasting more than 5 days.
Age: 0.17
Sex: U
Vaccine: HIBV
Symptoms: No adverse event, Poor quality product administered
Clinical narrative: ACTHIB was included in an excursion and was not viable anymore but it was administered to a patient before it was pulled out (with no reported adverse event); Initial information received on 05-Sep-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves acthib that was included in an excursion and was not viable anymore but it was administered to a 2 months old and unknown gender patient before it was pulled out (with no reported adverse event)   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included diphtheria vaccine toxoid, hepatitis B vaccine RHBSAG (YEAST), pertussis vaccine acellular 3-component, polio vaccine INACT 3V (VERO), tetanus vaccine toxoid (Pediarix); pneumococcal vaccine CONJ 13V (CRM197) (Prevnar 13); and rotavirus vaccine LIVE ORAL 1V (Rotarix) for Prophylactic vaccination.  On 05-Sep-2023, the patient received a dose 1, 0.5 ml of suspect HIB (PRP/T) Vaccine, Powder and solvent for solution for injection lot UJ835AA, expiry- 22-Feb-2024 via intramuscular route in the right thigh for Immunization, acthib was included in an excursion and was not viable anymore but it was administered to a patient before it was pulled out (with no reported adverse event) (poor quality product administered) (latency same day).  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event poor quality product administered  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: PNC15
Symptoms: Syringe issue
Clinical narrative: No additional AE reported; the nurse was placing the safety lock on syringe the barrel where the needle screws into the syringe broke /There is 1 unit with an alleged defect; Poor quality device used; This spontaneous report was received from a medical assistant (also reported as a nurse) referring to a patient of unknown age and gender. The patient's medical history, historical drugs, past drug reactions and allergies, concurrent conditions, and concomitant drugs were not reported.   On 06-SEP-2023, the patient was vaccinated with pneumococcal 15v conj vaccine (CRM197) (VAXNEUVANCE) injection (strength: 0.5 ml, 1 dose, product qty: 1, lot#: X005583, expiration date: 10-DEC-2024; route of administration was not reported) for prophylaxis. After the administration, when the nurse placed the safety lock on syringe, the barrel where the needle screwed into the syringe broke (also reported as "the part where the needle attached to broke off" and "broken syringe tip") (needle issue). There was 1 unit with an alleged defect. It was unsure whether the syringe had a broken component. The syringe tip cap was attached properly prior to use and intact, undamaged with seal on receipt. Complete vaccine was administered to the patient (poor quality device used). No dose was missed. No one was hurt, neither the nurse administering or the patient. It was "repeat user" who administered the vaccine. It was unsure whether the syringe had a broken component. No additional adverse event (AE) was reported (no adverse event). As of 07-SEP-2023, the product was being shipped back to manufacturer.
Sex: U
Vaccine: HIBV
Symptoms: No adverse event, Product preparation error
Clinical narrative: patient received ACT-HIB that was reconstituted with sterile water, not 0.4% NaCl diluent with no reported adverse event; Initial information received on 05-Sep-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves patient of an unknown age and unknown gender who received HIB (PRP/T) vaccine [ACT-HIB] that was reconstituted with sterile water, not 0.4% NaCl diluent with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received an unknown dose of suspect HIB (PRP/T) vaccine (Powder and solvent for solution for injection) (lot number; strength; expiry date not reported) via unknown route in unknown administration site for Immunization. Information regarding batch number will be requested in this case.  On an unknown date the patient received HIB (PRP/T) vaccine that was reconstituted with sterile water, not 0.4% NaCl diluent with no reported adverse event (product preparation error) (latency: same day).  It was reported, "Nurse reports that ACT-HIB was mixed with sterile water and administered to a patient; asks if that is still a viable vaccine or if the dose needs to be repeated?"   Action taken was not applicable.  At time of reporting, the outcome was Unknown for the event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 72.0
Sex: F
Vaccine: VARZOS
Symptoms: Confusional state, Dizziness, Headache, Malaise, Myalgia
Clinical narrative: Fever, muscle aches, headache, malaise, queasiness, dizziness, confusion, vomiting later in morning
Age: 72.0
Sex: F
Vaccine: VARZOS
Symptoms: Nausea, Pyrexia, Vomiting
Clinical narrative: Fever, muscle aches, headache, malaise, queasiness, dizziness, confusion, vomiting later in morning
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Amnesia, Chest pain
Clinical narrative: Possibly a year later, chest pain and memory loss.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine
Age: 12.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine
Age: 12.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Anticoagulant therapy, C-reactive protein increased, COVID-19 pneumonia, Chest X-ray abnormal, Cough
Clinical narrative: presented with cough x10 days; sob x2 days; dx Covid PNA; Labs: D-dimer 0.90; CRP 14.20; Ferritin 198 CXR: Bibasilar patchy opacities may represent pneumonia Tx: Steroids, lovenox, singulair, zinc (remdesivir not indicated due to timing of onset)   D/C on home O2
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Fibrin D dimer, Lung opacity, Serum ferritin normal
Clinical narrative: presented with cough x10 days; sob x2 days; dx Covid PNA; Labs: D-dimer 0.90; CRP 14.20; Ferritin 198 CXR: Bibasilar patchy opacities may represent pneumonia Tx: Steroids, lovenox, singulair, zinc (remdesivir not indicated due to timing of onset)   D/C on home O2
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, C-reactive protein increased, Chest X-ray abnormal, Fibrin D dimer, Mental status changes
Clinical narrative: presented with weakness, AMS; CXR: multifocal PNA, Labs:  CRP 18.96; Initially requiring 8 LPM O2; D-dimer 2.5; ferritin 4443; Tx:  Maxipime, rocephin, doxycycline, remdesivir,  Tocilizumab (1/28/); zinc, Vit C, solu-medrol, Down to 1 LPM O2 at D/C
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Pneumonia, Serum ferritin increased
Clinical narrative: presented with weakness, AMS; CXR: multifocal PNA, Labs:  CRP 18.96; Initially requiring 8 LPM O2; D-dimer 2.5; ferritin 4443; Tx:  Maxipime, rocephin, doxycycline, remdesivir,  Tocilizumab (1/28/); zinc, Vit C, solu-medrol, Down to 1 LPM O2 at D/C
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 84.0
Sex: M
Vaccine: COVID19
Symptoms: Chest X-ray normal, Decreased appetite, Fatigue
Clinical narrative: Presented with fatigue, dec appetite; CXR normal; No significant resp symptoms; remained on room air, no indication for steroids or remdesivir
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: C-reactive protein increased, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal, Chest pain
Clinical narrative: Presented with CP, cough, body aches; + covid in ED Labs: D dimer 1.15; CRP 24.48 Ferritin 4553 CXR: Diffuse bil infiltrates consistent with Covid PNA Tx: Rocephin, Remdesivir, Decadron, Merrem, singulair, zinc;  initially 6 LPM NC; back to room air by d/c
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Fibrin D dimer, Lung infiltration, Pain, SARS-CoV-2 test positive
Clinical narrative: Presented with CP, cough, body aches; + covid in ED Labs: D dimer 1.15; CRP 24.48 Ferritin 4553 CXR: Diffuse bil infiltrates consistent with Covid PNA Tx: Rocephin, Remdesivir, Decadron, Merrem, singulair, zinc;  initially 6 LPM NC; back to room air by d/c
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Serum ferritin increased
Clinical narrative: Presented with CP, cough, body aches; + covid in ED Labs: D dimer 1.15; CRP 24.48 Ferritin 4553 CXR: Diffuse bil infiltrates consistent with Covid PNA Tx: Rocephin, Remdesivir, Decadron, Merrem, singulair, zinc;  initially 6 LPM NC; back to room air by d/c
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Anticoagulant therapy, C-reactive protein increased, COVID-19, Chest X-ray abnormal, Dyspnoea
Clinical narrative: Presented with SOB x9 days; +Covid on 1/18; became more SOB on 1/23; CXR: bilat interstitial and alveolar infiltrates consistent with atypical multifocal PNA; CRP 17.43; D Dimer 0.55; Ferritin 3340  Tx: Zithromax, Rocephin, Decadron, Remdesivir, Vit C, Vit D3, Lovenox, Zinc; initially on 4 LPM with admission; up to 10 LPM and then back to2 LPM at d/c; home with home O2
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Fibrin D dimer, Lung infiltration, Pneumonia, SARS-CoV-2 test positive, Serum ferritin increased
Clinical narrative: Presented with SOB x9 days; +Covid on 1/18; became more SOB on 1/23; CXR: bilat interstitial and alveolar infiltrates consistent with atypical multifocal PNA; CRP 17.43; D Dimer 0.55; Ferritin 3340  Tx: Zithromax, Rocephin, Decadron, Remdesivir, Vit C, Vit D3, Lovenox, Zinc; initially on 4 LPM with admission; up to 10 LPM and then back to2 LPM at d/c; home with home O2
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 12.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 1.0
Sex: F
Vaccine: PPV
Symptoms: Wrong product administered
Clinical narrative: Patient administered Pneumovax 23 inadvertently vs Prenvar 20
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 10.0
Sex: F
Vaccine: DTAPIPV
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: Pt was given Quadracel which is only approved for children ages 4-6 years.  No further treatment was given.  No adverse reaction was noted.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: C-reactive protein, COVID-19 pneumonia, Chest X-ray abnormal, Dyspnoea, Pain
Clinical narrative: Presented with SOB/body aches x3 days; dx Covid PNA: Labs: CRP 5.31; Ferritin 2113; CXR: R lung pneumonia Tx: Maxipime, Decadron, Heparin, Singulair, Zinc (no remdesivir due to ESRD); Initially on 3 LPM O2; up to 5 LPM and then back to room air at d/c
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Serum ferritin increased
Clinical narrative: Presented with SOB/body aches x3 days; dx Covid PNA: Labs: CRP 5.31; Ferritin 2113; CXR: R lung pneumonia Tx: Maxipime, Decadron, Heparin, Singulair, Zinc (no remdesivir due to ESRD); Initially on 3 LPM O2; up to 5 LPM and then back to room air at d/c
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Vaccine.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: C-reactive protein increased, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal, Cough
Clinical narrative: presented with AMS, cough/SOB x3 days from oncologist office; +covid in ED; CXR: Covid 19 PNA; D-dimer 16.02; CRP  12.8; Ferritin 2036.3 Tx:  Initially on 6 LPM O2; up to High flow O2 60/50:  Rec'd Remdesivir, Vanc, Unasyn, Maxipime,  Decadron, Lovenox, 1/25 palliative care consult; DNR but continue aggressive measures; 1/27 comfort care1/28 inpatient hospice- died shortly after